A team of scientists has successfully developed a groundbreaking targeted therapy that hones in on the KRAS protein that drives some of the deadliest human cancers, including pancreatic, lung and colon tumors. Their findings suggest that a novel inhibitor drug could be used to target KRAS G12D, a subset of the notorious cancer-driving KRAS gene.